BACKGROUND: CD8 T-cell counts remain elevated in human immunodeficiency virus (HIV) infection even after long-term antiretroviral therapy (ART), which is associated with an increased risk of non-AIDS-related events. We assessed the impact of ART initiation in early versus chronic HIV infection on trajectories of CD8 cell counts over time. METHODS: Of 280 individuals enrolled during primary HIV infection (PHI), 251 were followed up for 24 months; 84 started ART before 6 months of infection (eART), 49 started between 6 and 24 months, and 118 remained untreated. Plasma HIV viral load (VL), CD4 and CD8 cell counts were assessed at each study visit. CD8 counts were also examined in 182 age-matched HIV-infected individuals who started ART during chronic infection and maintained undetectable plasma VL for ≥5 years. RESULTS: At PHI baseline, higher CD8 cell counts were associated with more recent infection (P = .02), higher CD4 cell counts (P < .001), and higher VL (P < .001). The CD8 count in the eART group decreased from 797 to 588 cells/µL over 24 months (P < .001), to a level lower than that in untreated PHI (834 cells/µL; P = .004) or in long-term-treated patients with chronic HIV infection (743 cells/µL; P = .047). More prominent CD4 T-cell recovery was observed in the eART group than in the delayed ART group. CONCLUSIONS: ART initiated in early HIV infection is associated with improved resolution of CD8 T-cell elevation compared with long-term ART initiated in chronic infection. Early ART may help reduce the risk of non-AIDS-related events by alleviating this elevation.
BACKGROUND:CD8 T-cell counts remain elevated in human immunodeficiency virus (HIV) infection even after long-term antiretroviral therapy (ART), which is associated with an increased risk of non-AIDS-related events. We assessed the impact of ART initiation in early versus chronic HIV infection on trajectories of CD8 cell counts over time. METHODS: Of 280 individuals enrolled during primary HIV infection (PHI), 251 were followed up for 24 months; 84 started ART before 6 months of infection (eART), 49 started between 6 and 24 months, and 118 remained untreated. Plasma HIV viral load (VL), CD4 and CD8 cell counts were assessed at each study visit. CD8 counts were also examined in 182 age-matched HIV-infected individuals who started ART during chronic infection and maintained undetectable plasma VL for ≥5 years. RESULTS: At PHI baseline, higher CD8 cell counts were associated with more recent infection (P = .02), higher CD4 cell counts (P < .001), and higher VL (P < .001). The CD8 count in the eART group decreased from 797 to 588 cells/µL over 24 months (P < .001), to a level lower than that in untreated PHI (834 cells/µL; P = .004) or in long-term-treated patients with chronic HIV infection (743 cells/µL; P = .047). More prominent CD4 T-cell recovery was observed in the eART group than in the delayed ART group. CONCLUSIONS: ART initiated in early HIV infection is associated with improved resolution of CD8 T-cell elevation compared with long-term ART initiated in chronic infection. Early ART may help reduce the risk of non-AIDS-related events by alleviating this elevation.
Authors: Sharat Srinivasula; Richard A Lempicki; Joseph W Adelsberger; Chiung-Yu Huang; Joshua Roark; Philip I Lee; Adam Rupert; Randy Stevens; Irini Sereti; H Clifford Lane; Michele Di Mascio; Joseph A Kovacs Journal: Blood Date: 2011-05-11 Impact factor: 22.113
Authors: Frederikke F Rönsholt; Henrik Ullum; Terese L Katzenstein; Jan Gerstoft; Sisse R Ostrowski Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane Journal: J Immunol Date: 2011-01-21 Impact factor: 5.422
Authors: Sergio Serrano-Villar; Carolina Gutiérrez; Alejandro Vallejo; Beatriz Hernández-Novoa; Laura Díaz; María Abad Fernández; Nadia Madrid; Fernando Dronda; Javier Zamora; María Ángeles Muñoz-Fernández; Santiago Moreno Journal: J Infect Date: 2012-10-06 Impact factor: 6.072
Authors: Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks Journal: PLoS Pathog Date: 2014-05-15 Impact factor: 6.823
Authors: Davey M Smith; Masato Nakazawa; Michael L Freeman; Christy M Anderson; Michelli F Oliveira; Susan J Little; Sara Gianella Journal: Clin Infect Dis Date: 2016-09-06 Impact factor: 9.079
Authors: Jintanat Ananworanich; Carlo P Sacdalan; Suteeraporn Pinyakorn; Nicolas Chomont; Mark de Souza; Tassanee Luekasemsuk; Alexandra Schuetz; Shelly J Krebs; Robin Dewar; Linda Jagodzinski; Sasiwimol Ubolyam; Rapee Trichavaroj; Sodsai Tovanabutra; Serena Spudich; Victor Valcour; Irini Sereti; Nelson Michael; Merlin Robb; Praphan Phanuphak; Jerome H Kim; Nittaya Phanuphak Journal: J Virus Erad Date: 2016
Authors: Genevieve E Martin; Debattama R Sen; Matthew Pace; Nicola Robinson; Jodi Meyerowitz; Emily Adland; John P Thornhill; Mathew Jones; Ane Ogbe; Lucia Parolini; Natalia Olejniczak; Panagiota Zacharopoulou; Helen Brown; Christian B Willberg; Nneka Nwokolo; Julie Fox; Sarah Fidler; W Nicholas Haining; John Frater Journal: Front Immunol Date: 2021-06-04 Impact factor: 7.561